WO2000007583A3 - Treatment of addiction and addiction-related behavior - Google Patents
Treatment of addiction and addiction-related behavior Download PDFInfo
- Publication number
- WO2000007583A3 WO2000007583A3 PCT/US1999/017220 US9917220W WO0007583A3 WO 2000007583 A3 WO2000007583 A3 WO 2000007583A3 US 9917220 W US9917220 W US 9917220W WO 0007583 A3 WO0007583 A3 WO 0007583A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- addiction
- gaba
- pharmaceutically acceptable
- effective amount
- gamma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000563268A JP2002522383A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction or addiction-related behavior |
IL14106799A IL141067A0 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
HU0103377A HUP0103377A3 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
MXPA01001268A MXPA01001268A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior. |
PL347912A PL198789B1 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
EP99941982A EP1102583B1 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction to nicotine and addiction-related behavior |
KR1020017001525A KR20010085332A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addition-related behavior |
DE69931789T DE69931789T2 (en) | 1998-08-05 | 1999-08-05 | TREATMENT OF NICOTINE ASK AND SEEK CONDITIONAL BEHAVIOR |
AU55452/99A AU772715B2 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
NZ509682A NZ509682A (en) | 1998-08-05 | 1999-08-05 | Method of treating addictive behaviour by administering a GVG drug also known as the epileptic vigabatrin (sabril) |
BR9912760-1A BR9912760A (en) | 1998-08-05 | 1999-08-05 | Uses of vinylgaba gamma (gvg) and a composition that increases gaba levels in the central nervous system |
CA002339192A CA2339192C (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
NO20010539A NO20010539L (en) | 1998-08-05 | 2001-01-31 | Treatment of addiction and addiction-related behavior |
HR20010085A HRP20010085A2 (en) | 1998-08-05 | 2001-02-02 | Treatment of addiction and addiction-related behavior |
CY20061101262T CY1105214T1 (en) | 1998-08-05 | 2006-09-05 | TREATMENT OF NICOTINE ADDICTION AND RELATED ADDICTIVE BEHAVIOR |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/129,253 | 1998-08-05 | ||
US09/129,253 US6057368A (en) | 1998-08-05 | 1998-08-05 | Treatment of addiction and addiction-related behavior |
US09/189,166 | 1998-11-09 | ||
US09/189,166 US6828349B1 (en) | 1998-08-05 | 1998-11-09 | Treatment of addiction and addiction-related behavior |
US09/209,952 | 1998-12-11 | ||
US09/209,952 US6541520B1 (en) | 1998-08-05 | 1998-12-11 | Treatment of addiction and addiction-related behavior |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000007583A2 WO2000007583A2 (en) | 2000-02-17 |
WO2000007583A3 true WO2000007583A3 (en) | 2000-09-08 |
Family
ID=27383860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017220 WO2000007583A2 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
Country Status (24)
Country | Link |
---|---|
US (4) | US6541520B1 (en) |
EP (1) | EP1102583B1 (en) |
JP (1) | JP2002522383A (en) |
CN (1) | CN1172663C (en) |
AT (1) | ATE328588T1 (en) |
AU (1) | AU772715B2 (en) |
BR (1) | BR9912760A (en) |
CA (1) | CA2339192C (en) |
CY (1) | CY1105214T1 (en) |
CZ (1) | CZ2001394A3 (en) |
DE (1) | DE69931789T2 (en) |
DK (1) | DK1102583T3 (en) |
ES (1) | ES2267287T3 (en) |
HR (1) | HRP20010085A2 (en) |
HU (1) | HUP0103377A3 (en) |
ID (1) | ID28916A (en) |
IL (1) | IL141067A0 (en) |
MX (1) | MXPA01001268A (en) |
NO (1) | NO20010539L (en) |
NZ (1) | NZ509682A (en) |
PL (1) | PL198789B1 (en) |
PT (1) | PT1102583E (en) |
TW (1) | TWI243674B (en) |
WO (1) | WO2000007583A2 (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
CA2341400A1 (en) * | 1998-08-25 | 2000-03-02 | Sepracor, Inc. | Methods and compositions employing optically pure s(+) vigabatrin |
JP2002527470A (en) * | 1998-10-20 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse |
MXPA01008537A (en) * | 1999-02-24 | 2005-02-17 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders. |
WO2000066108A2 (en) * | 1999-04-30 | 2000-11-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
IT1313585B1 (en) * | 1999-07-30 | 2002-09-09 | Neuroscienze S C A R L | USE OF GABAB RECEPTOR AGONISTS FOR THE MAINTENANCE THERAPY OF NICOTINE ABSTINENCE IN NICOTINO-EMPLOYEES. |
US6395783B1 (en) * | 2000-10-23 | 2002-05-28 | Brookhaven Science Associates, Llc | Treatment of PCP addiction and PCP addiction-related behavior |
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
US20020187996A1 (en) * | 2001-05-14 | 2002-12-12 | Dewey Stephen L. | Prevention of addiction in pain management |
US6462084B1 (en) * | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
US7041650B2 (en) | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7822470B2 (en) * | 2001-10-11 | 2010-10-26 | Osypka Medical Gmbh | Method for determining the left-ventricular ejection time TLVE of a heart of a subject |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
AU2003213719A1 (en) | 2002-03-01 | 2003-09-16 | Regents Of The University Of Michigan | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US6797707B2 (en) * | 2002-03-29 | 2004-09-28 | University Of Florida | Antagonists of RF-amide neuropeptides |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
CN100360117C (en) | 2002-06-21 | 2008-01-09 | 转化医药公司 | Pharmaceutical compositions with improved dissolution |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
AR055792A1 (en) * | 2005-05-17 | 2007-09-05 | Wm Internat Ltd | APPARATUS AND METHOD FOR THE NON-CHEMICAL STABILIZATION OF BIO-SOLIDS |
CN101754947A (en) | 2005-05-20 | 2010-06-23 | 詹森药业有限公司 | The preparation method of sulfone amide derivative |
EP1937236A2 (en) * | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
AR058389A1 (en) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
DE102006016990A1 (en) * | 2006-04-11 | 2007-10-18 | Hermann, Holger Lars, Dr. | Use of baclofen compounds to treat dependence on gamma-hydroxybutyrate or its analogs |
AU2007253814A1 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
US20080103111A1 (en) * | 2006-06-21 | 2008-05-01 | Harlan Clayton Bieley | Smoking Cessation Treatment with Appetite Suppression |
US20100021570A1 (en) * | 2006-06-21 | 2010-01-28 | Harlan Clayton Bieley | Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke |
US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
US20080194519A1 (en) * | 2006-09-15 | 2008-08-14 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
JPWO2008090736A1 (en) * | 2007-01-23 | 2010-05-20 | 公立大学法人名古屋市立大学 | Medicament for the prevention and treatment of Alzheimer type dementia |
EP2182804B1 (en) * | 2007-08-06 | 2017-05-24 | Biotie Therapies, Inc. | Methods for treating dependence |
WO2009051824A2 (en) * | 2007-10-18 | 2009-04-23 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
AU2009271362B2 (en) | 2008-06-23 | 2014-03-13 | Janssen Pharmaceutica Nv | Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
WO2011041451A2 (en) * | 2009-09-30 | 2011-04-07 | Harlan Clayton Bieley | Smoking cessation with body weight maintenance and nutritional supplement |
EP3064064A1 (en) * | 2009-09-30 | 2016-09-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
US20120046232A1 (en) * | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
CN104873455B (en) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | Coated Tamper Resistant Controlled Release Dosage Forms |
US9233073B2 (en) | 2010-12-23 | 2016-01-12 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
US20140072936A1 (en) * | 2012-09-07 | 2014-03-13 | Patrick D. Herron | Method of Tracking Consumption and Associated Effects |
MX366159B (en) | 2012-11-30 | 2019-07-01 | Acura Pharmaceuticals Inc | Self-regulated release of active pharmaceutical ingredient. |
EA201500742A1 (en) | 2013-02-05 | 2015-12-30 | Пердью Фарма Л.П. | PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
WO2015145459A1 (en) | 2014-03-26 | 2015-10-01 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
WO2015187289A1 (en) | 2014-06-03 | 2015-12-10 | Pop Test Abuse Deterrent Technology Llc | Drug device configured for wireless communication |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
CN114903006A (en) * | 2021-02-09 | 2022-08-16 | 中国科学院脑科学与智能技术卓越创新中心 | Construction method and application of non-human primate substance addiction model |
EP4334282A1 (en) * | 2021-05-05 | 2024-03-13 | Mind Medicine, Inc. | Mdma enantiomers |
CN115386421A (en) * | 2022-06-23 | 2022-11-25 | 江苏华熙益能生物科技有限公司 | Tobacco essence, preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0024965A1 (en) * | 1979-07-26 | 1981-03-11 | Merrell Toraude Et Compagnie | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them |
WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
EP0509180A1 (en) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639607A (en) | 1970-11-02 | 1972-02-01 | Jack E Phillips | Method for treating the tobacco smoking habit |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
GB2133002B (en) | 1982-12-30 | 1986-01-29 | Merrell Toraude & Co | Process for preparing 4-amino-5-hexenoic acid |
GB8311804D0 (en) | 1983-04-29 | 1983-06-02 | Merrell Toraude & Co | Treatment of seizure disorders and pharmaceutical compositions |
US4595697A (en) | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
GB9125615D0 (en) * | 1991-12-02 | 1992-01-29 | Wyeth John & Brother Ltd | Amines |
US5332736A (en) * | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
CO4970824A1 (en) | 1997-10-28 | 2000-11-07 | Schering Corp | METHOD TO REDUCE ANXIES OF CONSUMPTION IN MAMMALS |
JP2002527470A (en) | 1998-10-20 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful in the treatment of alcoholism, addiction and abuse |
MXPA01008537A (en) | 1999-02-24 | 2005-02-17 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders. |
WO2000066108A2 (en) | 1999-04-30 | 2000-11-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
-
1998
- 1998-12-11 US US09/209,952 patent/US6541520B1/en not_active Expired - Fee Related
-
1999
- 1999-07-28 US US09/362,592 patent/US6593367B1/en not_active Expired - Fee Related
- 1999-08-05 CA CA002339192A patent/CA2339192C/en not_active Expired - Fee Related
- 1999-08-05 WO PCT/US1999/017220 patent/WO2000007583A2/en not_active Application Discontinuation
- 1999-08-05 EP EP99941982A patent/EP1102583B1/en not_active Expired - Lifetime
- 1999-08-05 IL IL14106799A patent/IL141067A0/en unknown
- 1999-08-05 AT AT99941982T patent/ATE328588T1/en active
- 1999-08-05 CN CNB998117625A patent/CN1172663C/en not_active Expired - Fee Related
- 1999-08-05 DK DK99941982T patent/DK1102583T3/en active
- 1999-08-05 JP JP2000563268A patent/JP2002522383A/en active Pending
- 1999-08-05 DE DE69931789T patent/DE69931789T2/en not_active Expired - Lifetime
- 1999-08-05 PL PL347912A patent/PL198789B1/en not_active IP Right Cessation
- 1999-08-05 PT PT99941982T patent/PT1102583E/en unknown
- 1999-08-05 MX MXPA01001268A patent/MXPA01001268A/en not_active IP Right Cessation
- 1999-08-05 ID IDW20010504A patent/ID28916A/en unknown
- 1999-08-05 HU HU0103377A patent/HUP0103377A3/en unknown
- 1999-08-05 NZ NZ509682A patent/NZ509682A/en not_active IP Right Cessation
- 1999-08-05 AU AU55452/99A patent/AU772715B2/en not_active Ceased
- 1999-08-05 ES ES99941982T patent/ES2267287T3/en not_active Expired - Lifetime
- 1999-08-05 BR BR9912760-1A patent/BR9912760A/en not_active Application Discontinuation
- 1999-08-05 CZ CZ2001394A patent/CZ2001394A3/en unknown
- 1999-09-29 TW TW088113319A patent/TWI243674B/en active
-
2000
- 2000-08-09 US US09/635,578 patent/US6323239B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 NO NO20010539A patent/NO20010539L/en not_active Application Discontinuation
- 2001-02-02 HR HR20010085A patent/HRP20010085A2/en not_active Application Discontinuation
- 2001-02-02 US US09/776,117 patent/US6906099B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 CY CY20061101262T patent/CY1105214T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0024965A1 (en) * | 1979-07-26 | 1981-03-11 | Merrell Toraude Et Compagnie | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them |
WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
EP0509180A1 (en) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication |
Non-Patent Citations (12)
Title |
---|
DEWEY ET AL.: "A new GABAergic stategyfor treating cocaine addiction", J. NUCLEAR MED., vol. 39, no. 5suppl., May 1998 (1998-05-01), pages 99 - 100, XP000857227 * |
DEWEY ET AL.: "A novel strategy for the treatment of cocaine addiction", SYNAPSE, vol. 30, no. 2, October 1998 (1998-10-01), pages 119 - 129, XP000856612 * |
DEWEY ET AL.: "A pharmacologic strategy for the treatment of nicotine addiction", SYNAPSE, vol. 31, no. 1, January 1999 (1999-01-01), pages 76 - 86, XP000856613 * |
DEWEY ET AL.: "GABAergic attenuation of cocaine-induced dopamine release and locomotor activity", SYNAPSE, vol. 25, no. 4, 1997, pages 393 - 398, XP000856597 * |
KUSHNER ET AL.: "Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement", SOC. NEUROSCI. ABSTR., vol. 23, no. 1-2, 1997, pages 1942, XP002127040 * |
KUSHNER ET AL.: "Gamma-vinyl GABA attenuats cocaine-induced lowering of brain stimulation reward thresholds", PSYCHOPHARMACOLOGIA, vol. 133, no. 4, 11 November 1997 (1997-11-11), pages 383 - 388, XP000856604 * |
KUSHNER ET AL.: "The irreversible Gamma-aminobutyric acid (GABA) transaminase inhibitor Gamma-vinyl-GABA blocks cocaine self-administration in rats", J. PHARMACOL. EXP. THER., vol. 290, no. 2, 19 July 1999 (1999-07-19), pages 797 - 802, XP002127042 * |
MORGAN ET AL.: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine", SYNAPSE, vol. 28, no. 1, January 1998 (1998-01-01), pages 60 - 65, XP002127041 * |
MORGAN ET AL.: "Vigabatrin attenuates cocaine-induced changes in brain dopamine concentrations", J. NUCLEAR MED., vol. 38, no. 5suppl., 1997, pages 11p, XP000857224 * |
ROBERTS ET AL.: "Baclofen attenuates the reinforcing effects of cocaine in rats", NEUROPSYCHOPHARMACOLOGY, vol. 15, no. 4, 1996, pages 417 - 423, XP002127043 * |
TAKADA ET AL.: "Drug dependence study on Vigabatrin in Rhesus monkeys and rats", ARZNEIMITTEL FORSCHUNG, vol. 47, no. 10, October 1997 (1997-10-01), pages 1087 - 1092, XP000857211 * |
TSUJI ET AL.: "Activation of ventral tegmental GABA-B receptors inhibits morphine-induced place preference in rats", EUR. J. PHARMACOL., vol. 313, no. 3, 17 October 1996 (1996-10-17), pages 169 - 173, XP002127044 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000007583A3 (en) | Treatment of addiction and addiction-related behavior | |
Glick et al. | Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum | |
CA2278507A1 (en) | Method for treatment of cns-involved lysosomal storage diseases | |
EP2612553A1 (en) | Compositions and Methods for Prophylaxis and Treatment of Addictions | |
JP2002522383A5 (en) | ||
WO2000016762A3 (en) | Method for reducing nicotine dependency | |
US20070167438A1 (en) | Treatment of substance abuse | |
CA2193799A1 (en) | Dopamine d1 agonists for the treatment of dementia | |
US6890951B2 (en) | Treatment of addiction and addiction-related behavior | |
WO2000071108A3 (en) | Methods for treatment of asthma using s-oxybutynin | |
HK1024631A1 (en) | Use of (+) mefloquine for the treatment of malaria | |
WO2000010554A3 (en) | Methods and compositions employing optically pure s(+) vigabatrin | |
US4355044A (en) | D-Phenylalanine treatment | |
US6713497B1 (en) | Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals | |
WO2002091990A3 (en) | Prevention of addiction in pain management | |
US4431670A (en) | D-Phenylalanine treatment | |
McCarty | Nutritional support of central catecholaminergic tone may aid smoking withdrawal | |
YU9101A (en) | Treating of addiction and addiction-related behavior | |
EP0013110B1 (en) | Analgesic composition | |
AU2001292499A1 (en) | 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10- tetrahydropyridazino(4,5-b)quinoline-1,10-dione and the use thereof for the treatment of pain | |
AU2005237538B2 (en) | Methods of diminishing co-abuse potential | |
CA2345521A1 (en) | Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration | |
Ng et al. | On understanding and treating narcotic dependence: a neuropsychopharmacological perspective | |
Brown | Complications of regional blocks: what do we really know? | |
WO1999063935A3 (en) | Rapid opioid detoxification therapy and anti-readdiction therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-91/01 Country of ref document: YU Ref document number: 99811762.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 141067 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-394 Country of ref document: CZ Ref document number: 55452/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2339192 Country of ref document: CA Ref document number: 2339192 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509682 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001268 Country of ref document: MX Ref document number: P20010085A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017001525 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999941982 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999941982 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-394 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017001525 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 55452/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999941982 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017001525 Country of ref document: KR |